Industry-sponsored clinical drug studies are associated with publication of outcomes that favor the sponsor, even when controlling for potential bias in the methods used. However, the influence of sponsorship bias has not been examined in preclinical animal studies. We performed a meta-analysis of preclinical statin studies to determine whether industry sponsorship is associated with either increased effect sizes of efficacy outcomes and/or risks of bias in a cohort of published preclinical statin studies. We searched Medline (January 1966–April 2012) and identified 63 studies evaluating the effects of statins on atherosclerosis outcomes in animals. Two coders independently extracted study design criteria aimed at reducing bias, results for all relevant outcomes, sponsorship source, and investigator financial ties. The I2 statistic was used to examine heterogeneity. We calculated the standardized mean difference (SMD) for each outcome and pooled data across studies to estimate the pooled average SMD using random effects models. In a priori subgroup analyses, we assessed statin efficacy by outcome measured, sponsorship source, presence or absence of financial conflict information, use of an optimal time window for outcome assessment, accounting for all animals, inclusion criteria, blinding, and randomization. The effect of statins was significantly larger for studies sponsored by nonindustry sources (−1.99; 95% CI −2.68, −1.31) versus studies sponsored by industry (−0.73; 95% CI −1.00, −0.47) (p value<0.001). Statin efficacy did not differ by disclosure of financial conflict information, use of an optimal time window for outcome assessment, accounting for all animals, inclusion criteria, blinding, and randomization. Possible reasons for the differences between nonindustry- and industry-sponsored studies, such as selective reporting of outcomes, require further study.
Industry-sponsored clinical drug studies are associated with publication of outcomes that favor the sponsor, even when controlling for potential bias in the methods used. However, the influence of sponsorship bias has not been examined in preclinical animal studies. We performed a meta-analysis to identify whether industry sponsorship is associated with increased risks of bias or effect sizes of outcomes in a cohort of published preclinical studies of the effects of statins on outcomes related to atherosclerosis. We found that in contrast to clinical studies, the effect of statins was significantly larger for studies sponsored by nonindustry sources versus studies sponsored by industry. Furthermore, statin efficacy did not differ with respect to disclosure of financial conflict information, use of an optimal time window for outcome assessment, accounting for all animals, inclusion criteria, blinding, and randomization. Possible reasons for the differences between nonindustry- and industry-sponsored studies, such as selective outcome reporting, require further study. Overall, our findings provide empirical evidence regarding the impact of funding and other methodological criteria on research outcomes.
Citation: Krauth D, Anglemyer A, Philipps R, Bero L (2014) Nonindustry-Sponsored Preclinical Studies on Statins Yield Greater Efficacy Estimates Than Industry-Sponsored Studies: A Meta-Analysis. PLoS Biol 12(1): e1001770. doi:10.1371/journal.pbio.1001770
Academic Editor: Malcolm R. Macleod, University of Edinburgh, United Kingdom
Received: July 2, 2013; Accepted: December 9, 2013; Published: January 21, 2014
Copyright: © 2014 Krauth et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: National Institute of Environmental Health Sciences (Grant # R21ES021028) (http://www.niehs.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Abbreviations: ARRIVE, Animal Research: Reporting of In Vivo Experiments; CI, confidence interval; COI, conflict of interest; CONSORT, Consolidated Standards of Reporting Trials; MeSH, Medical Subject Heading; SMD, standardized mean difference
Preclinical studies are performed to evaluate a drug's efficacy in animal models . In addition, the results from animal studies are a critical—and often the only—input to evaluating potential toxicity of drugs before they proceed to human testing. Minimizing bias in the design, conduct, and reporting of preclinical animal research should produce more methodologically sound studies and results that provide better protection of humans from exposure to drugs tested in toxicology studies. Policies to reduce biases in preclinical animal studies should lead to the initiation of appropriate clinical trials that are an efficient use of resources and minimize risk to humans.
For the evaluation of human clinical research, there is a distinction between assessing risks of bias and methodological quality. Risks of bias are methodological criteria of a study that can introduce a systematic error in the magnitude or direction of the results . Some risks of bias in animal studies have been empirically identified. For example, analyses of animal studies testing interventions for stroke, multiple sclerosis, and emergency medicine have shown that lack of randomization, blinding of investigators, specification of inclusion and exclusion criteria for the animal subjects, statistical power, and failure to use comorbid animals are associated with inflated effect estimates of pharmaceutical interventions –. Using an optimal time window for outcome assessment and specifying whether all animals in the study are accounted for are also associated with reduced risks of bias ,. An assessment of a study's methodology also includes evaluation of additional study criteria related to how a study is conducted (e.g., in compliance with animal subjects guidelines) or reported (e.g., study population described).
Considerable evidence shows a strong association between industry sponsorship, investigator financial conflicts of interest (COIs), and biased outcomes in clinical research . Industry sponsorship biases the written research record towards outcomes that are favorable to the sponsor, even when controlling for study design criteria –. Financial ties between clinical researchers and industry have also been associated with reduced data sharing –. There is little evidence regarding the influence of these financial COIs on the integrity of preclinical animal studies.
Statins are an interesting class of drugs for investigating biases that influence research outcomes because there are a number of statins manufactured by competing companies; thus, there are financial incentives to develop statins that are more effective or safer than others. Previous research has shown that randomized controlled clinical trials of head-to-head comparisons of statins with other drugs are more likely to report results and conclusions favoring the sponsor's product compared to the comparator drug, even when controlling for other risks of bias . Clinically, statins are widely prescribed as effective agents for lowering cholesterol and other lipids. Statins have a number of other potential clinical uses that have been tested in animals including treating atherosclerosis, fracture healing, and endothelial dysfunction, and statins possess both anticarcinogenic and anticoagulant effects ,.
The objective of this study is to determine whether industry sponsorship is associated with increased effect sizes of efficacy outcomes and/or increased risks of bias in a cohort of published animal studies examining the effects of statins on atherosclerosis. We show that nonindustry-sponsored animal studies contained outcomes that were more favorable to the test statin compared to industry-sponsored studies and that statin efficacy did not differ between studies with high and low risks of bias.
As shown in Figure 1, we identified 4,592 potentially relevant studies. After screening study titles and abstracts, 71 citations containing atherosclerosis outcomes met our inclusion criteria and were identified for full text evaluation. After reviewing the full text, eight studies did not meet our inclusion criteria and were excluded. Overall, 63 total articles were included in this study. Of these 63 articles, 54 had quantitative data and 49 had analyzable data for the meta-analysis.
N indicates the number of studies.
Table 1 shows the frequencies of the study design criteria of included studies by sponsorship source. Only three of the 63 included studies were sponsored solely by industry sources, although 16 were partially sponsored by industry. The majority of studies (35 of 54 studies; 64.8%) that reported quantitative results reported results that favored statins. Similarly, 52 of 63 studies contained author conclusions that favored statin use.
The most commonly researched statin was simvastatin, evaluated in 31% (15 of 49) of studies, followed by pravastatin (24%, 12/49), and atorvastatin (20%, 10/49). Other statins studied included fluvastatin (12%, 6/49), lovastatin or rosuvastatin (8%, 4/49), and cerivastatin or pitavastatin (6%, 3/49). Of the 63 studies, five studies – evaluated multiple statins, of which four were included in the meta-analysis –,.
Overall, test animal characteristics and a description of the animal environment were the most commonly reported criteria [62 of 63 studies (98.4%) and 60 of 63 studies (95.2%), respectively].
Specific Measures by Category of Outcome
The results were classified into the following categories, many of which contained multiple measures: (1) vessel measure, (2) plaque measure, (3) incidence of lesions, (4) occlusion, (5) plaque type/severity, (6) coronary stenosis, and (7) plaque stability.
Vessel measures included a myriad of outcomes: aortic lesion development, intima/media ratios, intimal thickening, maximal thickness, vessel wall area, lumen area, media size, carotid plaque, thickness of elastic layer, external diameter, aortic peak velocity (Vp), mean velocity (Vm), velocity time integral (VTI), and the external elastic membrane area (EEMA). Plaque measures included atherosclerosis plaque/lesion/surface area/thickness, plaque volume, aorta/artery maximum thickness, aorta/artery plaque volume, perimeter of plaque, average size of individual lesions, fatty streak area, frequency of lesions with hemorrhage, necrotic area, area of atheroma, and large necrotic core. Lastly, other measures included occlusion and fibrous cap measures.
The most commonly reported outcome categories were plaque measures, which were reported in 50 of 63 studies (79.4%), and vessel measures, which were reported in 26 of 63 studies (41.3%). Six studies (9.5%) reported coronary stenosis outcomes, whereas five studies (7.9%) reported plaque stability outcomes. Other outcome categories reported in identified studies were plaque type/severity (n = 4; 6.3%), incidence of lesions (n = 2; 3.2%), and occlusion outcomes (n = 1; 1.6%).
Animal Species Studied
Various rabbit species were studied in 55.6% (35 of 63) of studies and mice in 31.7% (20 of 63) of studies. Other species studied included hamsters (n = 2), monkeys (n = 2), rats (n = 2), chickens (n = 1), and guinea pigs (n = 1).
Overall, only 1.6% (1 of 63) of studies disclosed a financial COI of authors, 15.9% (10 of 63) of studies stated that all authors had no COIs to report, and 82.5% (52 of 63) of studies did not have any COI disclosure statement.
Role of the Financial Sponsor
Among the 47 studies with a disclosed sponsor of any type, 45 studies (95.7%) did not mention whether the sponsor was involved in the study, one study (2.1%) explicitly stated that the sponsor was not involved in the study, and one study (2.1%) stated that the sponsor was involved in the study.
Results and Conclusions Reported
Among studies with quantitative results and any disclosed sponsorship (n = 42), nearly half of studies with some industry sponsorship reported favorable results (n = 9 of 19 studies; 47%), whereas 72% (n = 18 of 25 studies) of nonindustry-sponsored studies reported favorable results. The relative risk of having favorable results when comparing industry-sponsored studies to studies without industry sponsorship was RR = 0.74 (95% CI 0.44–1.23).
Studies with some industry sponsorship were more likely to have conclusions that favored the statin (18 of 19 studies, 94.7%) than studies sponsored by nonindustry sources (21 of 28 studies, 75.0%). The relative risk of having favorable conclusions when comparing industry-sponsored studies to studies without industry sponsorship was RR = 1.26 (95% CI 0.99–1.60).
As shown in Figure 2, across all studies with analyzable results (49 studies with 184 outcomes measured in 954 animals), the pooled effect significantly favors statin use for atherosclerosis-related efficacy outcomes (−1.25; 95% CI −1.56, −0.94), with substantial heterogeneity (I2 = 73%). Ninety-four percent (n = 46 of 49) of average effects yielded point estimates favoring statins, whereas 6% of average effects yielded point estimates favoring controls.
A Priori Subgroup Analyses
As shown in Figure 2, the effect of statins is greater in studies with nonindustry sponsorship versus industry-sponsored studies (test for subgroup differences: p value<0.001) and in studies with nonindustry sponsorship versus studies with no sponsorship statement (test for subgroup differences: p value = 0.006). The effect of statins does not differ between studies with industry sponsorship and studies with no sponsorship statement (test for subgroup differences: p value = 0.36).
Using the 49 studies with analyzable results, we also conducted a sensitivity analysis using more specific sponsorship groupings: industry sponsored (n = 3), combined industry and nonindustry sponsored (n = 12), nonindustry sponsored (n = 23), and no funding statement (n = 11). This analysis yielded similar results between studies with industry sponsorship alone and studies with both industry and nonindustry sponsorship (industry sponsorship alone: 0.73 95% CI −1.00, −0.47; I2 = 18%; and industry and nonindustry sponsorship: 0.67 95% CI −1.00, −0.35; I2 = 29% versus nonindustry sponsorship: −1.99 95% CI −2.68, −1.31; I2 = 84%; tests for subgroup differences: p value<0.001). Furthermore, grouping studies with no financial statement with industry-sponsored studies also yielded similar results (industry sponsorship: 0.81 95% CI −1.01, −0.60; I2 = 111% versus nonindustry sponsorship: −1.99 95% CI −2.68, −1.31; I2 = 84%; test for subgroup differences: p value<0.001).
As shown in Figure 2, the effect of statins is greater in studies with only plaque or vessel measures versus combined measures (tests for subgroup differences: p value = 0.03).
Year of publication.
The studies were published between 1991 and 2012. As shown in Figure 2, studies published between 2010 and 2012 yielded greater efficacy estimates than studies published before 2010 (p = 0.07). Although we hypothesized that more recent studies would have lower risks of bias given that the Animal Research: Reporting In Vivo Experiment (ARRIVE) Guidelines for reporting animal research were introduced in 2010, we found that only randomization, whether all animals were accounted for, and sample size were reported more frequently after publication of the ARRIVE Guidelines. Randomization was reported in 11 of the 15 (73.3%) studies that were published post-ARRIVE compared to 19 of the 48 (39.6%) studies published pre-ARRIVE. All animals were accounted for in 12 of the 15 (80%) studies published post-ARRIVE compared to 27 of the 48 (56.3%) studies published pre-ARRIVE. Sample size was reported in all 15 studies published post-ARRIVE compared to 41 of 48 studies (85.4%) published pre-ARRIVE.
As shown in Figure 2, studies with financial COI disclosures, optimal timing of outcome measures, all animals accounted for, stated inclusion criteria, blinding, or randomization did not show greater efficacy of statins compared to studies without these criteria. In only one study did an author disclose a financial COI; therefore, subgroup analysis by this criterion was not performed. Instead, we conducted a subgroup analysis by whether the study contained a COI statement or not. The effect of statins is not different in studies with no financial conflict compared to studies with no conflict statement (test for subgroup differences: p value = 0.44). The effect of statins is not different in studies with optimal timing of outcome measurement compared to studies without optimal timing (test for subgroup differences: p value = 0.66), in studies with all animals accounted for compared to studies that did not account for all animals (p value = 0.74), in studies with no inclusion criteria described compared to studies with partial inclusion criteria (p value = 0.37), or in studies with blinding compared to studies with no blinding (p value = 0.81). No studies had full randomization. The effect of statins is not different in studies with partial randomization compared to studies with no randomization (p value = 0.19).
Risks of Bias by Sources of Sponsorship
To explore the differences in risks of bias between studies reporting different sources of sponsorship, we compared pooled efficacy estimates from studies with sponsorship from industry, nonindustry source(s), or no sponsorship statement stratified by risks of bias that are associated with effect size: randomization (partial versus no randomization), blinding of investigators (yes versus no), and all animals accounted for (yes versus no).
Comparisons between nonindustry-sponsored studies and studies sponsored by industry sources yielded higher efficacy estimates for statins in nonindustry-sponsored studies with partial randomization (test for subgroup difference: p = 0.008). Similarly, comparison between nonindustry studies with no randomization and studies sponsored by industry sources with no randomization yielded higher efficacy estimates for statins in nonindustry studies (test for subgroup difference: p = 0.06).
Comparisons between industry-sponsored studies and nonindustry-sponsored studies remained significantly different, yielding higher efficacy estimates for statins in nonindustry-sponsored studies with blinding (test for subgroup difference: p = 0.002).
Comparisons between industry-sponsored studies and nonindustry-sponsored studies remained significantly different, yielding higher efficacy estimates for statins in nonindustry-sponsored studies with all animals accounted for (test for subgroup difference: p = 0.001).
Sensitivity Analysis Using Fixed Effect Model
We performed a sensitivity analysis using a fixed-effects model rather than a random-effects model to evaluate differences in pooled estimates. The pooled effect of statins on the risk of atherosclerosis using a fixed-effects model was more attenuated (SMD = −1.01; 95% CI −1.17, −0.86) than the random-effects model (SMD = −1.25; 95% CI −1.56, −0.94). Similarly, the pooled effect among nonindustry-sponsored studies using a fixed-effects model was less (SMD = −1.44; 95% CI −1.70, −1.17) than the random-effects model (SMD = −1.99; 95% CI −2.68, −1.31). The pooled effect among industry-sponsored studies remained nearly unchanged (SMD = −0.72; 95% CI −0.96, −0.48 versus SMD = −0.73; 95% CI −1.00, −0.47). Tests of significance comparing subgroups remained significant in fixed-effects models.
Nonindustry-sponsored studies yielded greater efficacy estimates than industry-sponsored studies. Despite subgroup analyses by risks of bias, including financial COI information, optimal timing of outcome measurement, accounting for all animals, inclusion criteria, blinding, and randomization, efficacy estimates for nonindustry-sponsored studies remained significantly greater than industry-sponsored studies. This finding does not correspond to clinical studies that have examined sponsorship bias. Reviews of clinical drug studies have shown that industry funding sources and financial ties of investigators (including university- or industry-affiliated investigators) are associated with increased treatment effect sizes and other favorable outcomes for the sponsors . One reason for the discrepancy between the association of funding source and outcome in preclinical and clinical studies could be that the interests of the pharmaceutical industry are best served by underestimating efficacy prior to clinical trials and overestimating efficacy in clinical trials. By underestimating efficacy in preclinical studies, the pharmaceutical industry could reduce the money spent on clinical trials that did not lead to marketable products. By overestimating efficacy in clinical trials, the pharmaceutical industry could skew the evidence towards findings that would lead to drug approval and a marketable product.
Another possible explanation for our finding that nonindustry-sponsored studies demonstrated greater efficacy than industry-sponsored studies, independent of other risks of bias, is that an overwhelming number of studies in our sample had statistically significant results in favor of the test statin. Ninety-four percent (n = 46 of 49) of studies yielded point estimates favoring statins. This finding is consistent with research demonstrating that the vast majority of clinical studies report statistically significant results for the interventions . Similarly, overly optimistic findings in animal studies could skew the data and send potentially ineffective drugs to clinical trials. Several studies have shown that favorable findings in animal studies often are not reproduced in clinical trials –.
Among clinical studies, most discovered true associations are inflated due to methodological flaws . Although we could not detect differences in risks of bias between the nonindustry- and industry-sponsored studies in our sample, substantial risks of bias existed across all studies. For example, none of the studies in our sample included sample size calculations, conducted intention-to-treat analysis, or had concealment of allocation. Approximately half of the studies did not report randomization, blinding of investigators, or the inclusion and exclusion criteria for the animal subjects.
Our inability to detect an association of risks of bias with effect sizes might be due to the poor reporting of these criteria. Among the 36 journals where the 63 studies were published, we determined that eight journals (22.2%) required only that authors report compliance with animal welfare regulations in their article, 17 (47.2%) had specific reporting requirements, and 11 (30.6%) did not have any reporting requirements. Recent calls for reporting criteria for animal studies recognize the need for the adoption and enforcement of journal reporting standards ,. In clinical research, reporting of risk of bias criteria improved as investigators began performing risk of bias assessments for systematic reviews and other purposes and journals began adopting reporting standards . As happened for clinical research, reporting of animal research is also likely to improve if risk of bias assessments becomes more common.
Reporting biases (i.e., failure to publish entire studies or selective outcome reporting) could explain the skewing of our sample towards favorable results and the very small proportion of industry-sponsored studies identified. The effect of publication bias has been documented in both animal and clinical studies. Studies of reporting biases in clinical research have shown that industry-sponsored clinical trials are less likely to be published in full than studies with other sponsors –. Similarly, a meta-analysis of animal studies assessing interventions for stroke showed that publication bias could account for at least a third of the efficacy reported in systematic reviews of animal stroke studies . Furthermore, data from a national survey of all animal laboratories in the Netherlands indicate that publication bias appears to be more prevalent in industry-sponsored animal research relative to animal research sponsored by nonindustry sources .
Our analysis of the direction of outcomes showed that industry-sponsored studies were less likely to have results that favored the statin, but more likely to have conclusions favoring the statin, compared to studies sponsored by nonindustry sources. The greater discordance between results and conclusions in industry-sponsored studies compared to nonindustry-sponsored studies has also been observed in meta-analyses of randomized controlled trials and trials of drugs conducted in human ,. The presence of “spin” in the conclusions of randomized trials—that is, specific reporting strategies to highlight that the experimental treatment is effective despite a statistically nonsignificant effect for the primary outcome—has been demonstrated . Further analysis of spin in the conclusions of animal studies is warranted.
Our study reveals a lack of reporting of harm-related metrics. Not a single study in our cohort assessed adverse events following the statin intervention; all 63 studies were nonequivalence efficacy studies. As toxicity data from animal studies must be submitted to drug regulatory authorities before a compound can proceed to testing in humans, it is surprising that so little data on harm appear in the published scientific literature. Although only one out of 22 study criteria from the Consolidated Standards of Reporting Trials (CONSORT) checklist addresses reporting of drug harms, attempts have been made to improve reporting of harm data .
This study has a few limitations. We restricted our search to the Medline database. Although we may have retrieved further studies had we searched additional databases, we found a sufficient number of studies (n = 63) to test our hypothesis examining the association of industry sponsorship, risks of bias, and research outcomes. Many of the studies we included had small samples sizes and measured multiple outcomes in a single animal. Therefore, when combining outcome measures within studies, we were unable to avoid double-counting animals within studies. We obviated this issue by averaging effect estimates and variances within studies. It should be noted that variances of SMDs are expected to be similar for different outcomes on the same animals. Therefore, the average variance across multiple outcomes should be similar to the variance for one outcome. Some outcomes were excluded from the meta-analyses due to missing data or the type of outcome estimates calculated. Thus, it is possible that our analyses overrepresented studies and outcomes with analyzable data.
Additionally, the types of statins compared between studies varied. Although the aim of this study was not to compare the efficacy of specific types of statins, we acknowledge the possibility of added heterogeneity due to unequal efficacy between statin types. Additional heterogeneity was likely present due to differences in or inadequate descriptions of the control groups in the studies.
Nonindustry-sponsored studies demonstrated greater efficacy than industry-sponsored studies, independent of other risks of bias. Because demonstrating drug efficacy in human studies is linked to drug company profits, drug companies may have more incentive to publish favorable efficacy findings of human drug studies than animal studies. Overall, the influence of funding source, risks of bias (such as lack of randomization and blinding), overwhelming proportion of studies reporting statistically significant efficacy outcomes, and lack of reporting of harm outcomes suggest a need for improving the integrity of preclinical animal research.
Materials and Methods
The selection criteria for studies, data extraction, and analyses were all determined a priori. A completed PRISMA checklist for this study can be found in Text S2.
We searched for all nonhuman animal (e.g., mice, rabbits, hamsters, monkeys, rooster, and chicken) studies of statins that compared a statin to a nonstatin comparator drug or placebo and measured outcomes for atherosclerosis. We identified studies testing the following statins: atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin. We did not exclude any type of statins.
We reviewed abstracts of all citations and retrieved studies based on the following inclusion criteria: (1) study conducted in animals; (2) original research, defined as a study that presented original data and did not specifically state that it was a review; (3) statin drug compared to either a nonstatin drug or placebo; (4) efficacy and/or harm outcomes measured; and (5) assessed effect of statin on at least one clinically relevant atherosclerosis-related outcome (including vessel measures, plaque measures, incidence of lesions, measurements of occlusion, plaque type/severity, coronary stenosis, and/or plaque stability).
Studies with the primary objective of assessing the effect of a combination of a statin and another drug were included if a comparison between a statin-only treatment group and the other drug was made.
Studies were excluded if they met any of the following criteria: (1) pharmacokinetic or pharmacodynamic studies; (2) editorials, letters to the editor, commentaries, abstracts, unpublished reports, systematic reviews, and meta-analyses; (3) studies only comparing different doses of one type of statin; (4) studies only comparing statins to a nondrug intervention (e.g., diet, exercise); (5) studies in which the statin was present in all the comparison groups; (6) in vitro analysis; and (7) studies with no comparison groups.
Initially, abstracts and study titles were reviewed, and only those studies meeting our inclusion criteria were further scrutinized by reading the full text. Any studies that did not clearly meet the criteria after review of the full text were discussed by two authors and a decision was made about inclusion.
We searched Medline from January 1966 to April 2012 using a search term combination developed with input from expert librarians. Our search strategy contained the following Medical Subject Heading (MeSH) terms, text words, and word variants:
- (atorvastatin OR cerivastatin OR fluvastatin OR lovastatin OR mevastatin OR pitavastatin OR pravastatin OR rosuvastatin OR simvastatin OR hydroxymethylglutaryl-CoA reductase inhibitors) AND (animal* OR preclinical OR “pre-clinical” OR mice OR rats OR rabbits OR dog OR dogs OR monkey OR monkeys OR “animal experimentation”[MeSH Terms] OR “models, animal”[MeSH Terms] OR “invertebrates”[MeSH Terms] OR “Animals”[MH] OR “animal population groups”[MeSH Terms]) NOT (humans[mh] NOT animals[mh:noexp]) AND (health effect OR health effects OR toxic OR toxicity OR toxicities OR efficacy OR efficacies OR toxicology OR safety OR harm* OR drug effects[sh] OR therapeutic use[sh:noexp] OR adverse effects[sh] OR poisoning[sh] OR pharmacology[sh:noexp] OR chemically induced[sh]) AND eng[la] NOT review[pt] NOT systematic review* NOT meta-analysis[pt]
For single-coded data collection, the following characteristics were collected from each included study by a single coder (D.K.):
Title of the study, month of publication, year of publication, and journal name.
The affiliation(s) of the author(s) was obtained from the study by-line and classified into (1) industry, if all authors were employed by industry; (2) nonindustry, if no author was employed by industry; or (3) combined if at least one author was employed by industry and at least one author was not employed by industry. If a single author had affiliations with industry and nonindustry sources, the study was coded as “combined.”
Study design criteria.
For each study, the following study design criteria were collected: (1) name of statin used in the study; (2) the comparison groups (e.g., comparator statin, active comparator nonstatin drug, or placebo); (3) animal species and strain used in the study; (4) number of control and treated animals at the start of the study; (5) type of study defined as a harm study, efficacy study, or both; and (6) whether the outcome data that we collected were the result of a laboratory analysis or a test to evaluate the effects of drug treatment on morbidity or mortality. We identified outcome data as “laboratory analysis” if an investigator measured the area of an atherosclerotic lesion, plaque thickness, intima/media thickness levels, or other related atherosclerosis outcomes in vivo. If an investigator recorded the occurrence of statin-induced morbidity (e.g., tumor progression, neurological damage, etc.) or mortality, we coded the analysis as “morbidity” or “mortality,” respectively.
Double-Coded Data Collection
Two coders (D.K. and R.P.) extracted data on risks of bias, effect size measurements for statin efficacy/harm outcomes, study sponsorship source(s), investigator financial ties, and author conclusions. The two coders worked independently and any discrepancies were discussed and adjudicated with a third coder making the decision if the discrepancy could not be resolved. The data extraction coding book is included in Text S1 .
Study Design Criteria to Assess Risks of Bias and other Methodological Criteria
We developed a set of core risk of bias criteria using findings from our published systematic review of assessment instruments for animal research . Among the 30 instruments evaluated in that review, the most commonly included criteria are randomization (included in 25 of 30 instruments), investigator blinding (23 of 30), and sample size calculation (18 of 30) , each of which are included in this study. We also assessed several other empirically tested criteria that are known to influence research outcomes in animal research and/or are related to favorable results or conclusions in clinical drug studies ,,,,–.
Some criteria included in our list are not associated with bias. For example, a statement of compliance with animal welfare requirements is a reporting issue. We included this criterion in our study as it was the most commonly required reporting criterion by the 36 journals that published the 63 studies included in this analysis. Similarly, although a sample size calculation is not associated with bias—as bias is not the same as imprecision—we included this criterion, as it is an important characteristic to consider in evaluating an overall body of evidence .
All criteria were coded as (1) yes, if the criterion was met; (2) no, if the criterion was not met; and when applicable (3) partial, if the criterion was partially met. The following criteria were assessed for each publication:
Was the treatment randomly allocated to animal subjects so that each subject has an equal likelihood of receiving the intervention? Randomization was coded as (1) yes, (2) no, and (3) partial.
Concealment of allocation.
Were processes used to protect against selection bias by concealing from the investigators how treatment was allocated at the start of the study? Concealment of allocation was coded as (1) yes, (2) no, and (3) partial.
Was the investigator(s) involved with performing the experiment, collecting data, and assessing the outcome of the experiment unaware of which subjects received the treatment and which did not? Blinding was coded as (1) yes, (2) no, and (3) partial.
Test animal description.
Did the author(s) describe in detail the test animal characteristics including the animal species, strain, substrain, genetic background, age, supplier, sex, and weight. At least one of these characteristics must be present for this criterion to be met. Test animal description was coded as (1) yes, (2) no, and (3) partial.
Did the author(s) adequately describe the housing and husbandry, nutrition, water, temperature, and lighting conditions? At least one of these characteristics must be present for this criterion to be met. Environmental parameters were coded as (1) yes, (2) no, and (3) partial.
Were criteria used for including or excluding subjects specified? Inclusion/exclusion criteria were coded as (1) yes, (2) no, and (3) partial.
Was an appropriate dose-response model used given the research question and disease being modeled? Dose/response model was coded as (1) yes and (2) no.
All animals accounted for.
Did the investigator account for attrition bias by detailing when animals were removed from the study and for what reason they were removed? All animals accounted for was coded as (1) yes, (2) no, and (3) partial.
Did the author(s) perform an intention-to-treat analysis (ITT)? ITT was coded as (1) yes, (2) no, and (3) partial.
Optimal time window investigated.
Did the investigator provide sufficient time to pass before assessing the outcome? The optimal time window used in animal research should reflect the time needed to see the outcome. Optimal time window investigated was coded as (1) yes, (2) no, and (3) partial.
Statement of compliance with animal welfare requirements.
Did the author(s) state whether or not they complied with regulatory requirements for the handling and treatment of test animals? Statement of compliance with animal welfare requirements was coded as (1) yes or (2) no.
Coding of Results
Only results for atherosclerosis-related outcomes were recorded. If multiple time points were reported, we included all time points in the meta-analysis as to not assume a primary endpoint or arbitrarily assign an endpoint in the analysis. For each result we collected the raw data (often derived from tables, graphs, figures, etc.), measure of effect, confidence interval, measure of variability, p value, and statistical test used.
Each outcome was assigned to one of the following categories: (1) vessel measure, (2) plaque measure, (3) incidence of lesions, (4) occlusion, (5) plaque type/severity, (6) coronary stenosis, and (7) plaque stability.
Results were then categorized as (1) favorable, if the result was statistically significant (p<0.05) and in the direction of the statin being more efficacious or less harmful (in the case of adverse effects); (2) unfavorable, if the result was not statistically significant (p>0.05) or significant in the wrong direction (e.g., statin statistically more harmful than nonstatin treatment group); and (3) neutral, if the statin was significantly different in the direction favoring the statin against one control group (e.g., early control) but not significantly different compared to a second control group (e.g., late control).
If an outcome was measured over multiple time points or concentrations, it was categorized as (1) favorable if at least one measurement was in favor of the statin or (2) unfavorable if there were no measurements in favor of the statin.
For the meta-analysis, for each included result, we extracted data for mean outcome, standard deviation (SD) or standard error (SE), and the number of treated and untreated animals.
The source of sponsorship for each study was categorized as (1) any industry, (2) nonindustry, (3) no sponsorship statement, and (4) no sponsorship.
Financial Ties of Authors
Information about financial ties was coded as (1) at least one author of the study reported having a financial COI, (2) all authors reported having no COIs, and (3) there was no disclosure statement.
Role of the Financial Sponsor
For studies with a disclosed sponsor of any type, the role of the sponsor was categorized as (1) not mentioned, (2) statement that the sponsor was not involved, and (3) statement that the sponsor was involved. When applicable, we reported specifically how the sponsor was involved (e.g., in the design, analysis, or dissemination of the study).
Author Conclusion of Included Study
For each published article, author conclusions were categorized as (1) favorable to the statin if the overall conclusion suggested that the statin is efficacious and safe. Conclusions were also favorable if the data empirically supported an author's hypothesis that the statin was efficacious and/or safe. For studies containing combination therapies (e.g., statin combined with another nonstatin drug), conclusions were coded as (1) favoring the statin if the author's hypothesis that the drugs have synergistic effects was supported; (2) unfavorable to the statin if the overall conclusion suggested that the statin is not efficacious or safe, less effective or safe relative to the active comparator, or if the author's hypothesis was not supported; and (3) neutral to the statin if the authors did not draw a conclusion regarding the statin or stated that the limitations of the study were so severe that the results were not valid. Conclusions were also neutral if the hypothesis or conclusion did not mention the statin or if the statin was considered comparable (in efficacy or toxicity) to the active comparator.
We report the frequencies of each study design criterion and the coding of the results and conclusions by sponsorship source.
To test our hypothesis that industry sponsorship is associated with increased effect sizes of efficacy outcomes and/or increased risks of bias, we conducted a meta-analysis of the studies that had analyzable data. For a study to have analyzable data, an author needed to report both a mean value and a measure of dispersion (standard error or standard deviation) or provide adequate data so that we could calculate these measures ourselves. Not all studies containing quantitative (numerical) data had analyzable data.
We calculated the effect of statins using an SMD for each outcome. Due to the lack of independence of animals between outcomes within studies, we averaged SMDs and variances across outcomes for each study, yielding k average SMDs and variances for k studies. We pooled the data across studies and estimated summary average SMDs using random-effects models . Specifically, we estimated the average SMD for each included study and used the inverse variance method to calculate study weights. The inverse variance method assumes that the variance for each study is inversely proportional to its importance; therefore, more weight is given to studies with less variance than studies with greater variance. The SMD null hypothesis (Ho: estimate = 0) states that there is no difference in effect of statin use on risk of atherosclerosis when compared to a control/placebo. A number less than zero suggests that the statin reduces the risk of atherosclerosis when compared to control or placebo. A number greater than zero suggests that the statin increases the risk of atherosclerosis when compared to the control or placebo.
We examined heterogeneity among the studies using the I2 statistic. We interpreted an I2 estimate greater than 50% as indicating moderate or high levels of heterogeneity. We anticipated high levels of heterogeneity as previous meta-analyses of animal studies have found high levels of heterogeneity between studies, potentially resulting from typical, small sample sizes in animal models .
We further investigated the potential causes of heterogeneity by conducting a priori subgroup analyses using the χ2 statistic with a significance level of 0.10. We conducted a subgroup analysis by type of outcome measure because we hypothesized that the efficacy of statins could vary by outcome. We performed subgroup analyses by study criteria that we hypothesized would be associated with effect sizes: financial ties of authors, sponsorship source, optimal timing, accounting for all animals, inclusion criteria, blinding, and randomization. We also performed a subgroup analysis by date of publication as we hypothesized that more recent studies would have lower risks of bias given that the ARRIVE Guidelines for reporting animal research were introduced in 2010. We assessed whether or not authors reported the following criteria more frequently postpublication of the ARRIVE Guidelines: a statement by authors regarding the ethical treatment of animals, a description of the test animal characteristics, environmental parameters, sample size, randomization, blinding of investigators, all animals accounted for, and inclusion/exclusion criteria.
We evaluated differences in pooled effect estimates between declared sponsorship sources by risk of bias criteria to determine if the effect between sponsorship sources differed by specific risks of bias.
The data extraction coding book is included in Text S1.
A completed PRISMA checklist for this study.
The authors acknowledge Gloria Won (UCSF Mount Zion Campus) for her assistance with developing the search strategy and Dr. Jeppe Schroll (The Nordic Cochrane Centre), Jane Ye (VA Palo Alto Health Care System), and Chia-An Lin (UC Berkeley) for reviewing drafts of our manuscript.
The author(s) have made the following declarations about their contributions: Conceived and designed the experiments: DK AA LB. Performed the experiments: DK AA RP. Analyzed the data: AA. Contributed reagents/materials/analysis tools: AA. Wrote the paper: DK AA RP LB.
- 1. Lo B, Field M (2009) COI in medical research, education, and practice. Washington, DC: The National Academies Press Institute of Medicine.
- 2. Higgins JP, Green S (2008) Cochrane handbook for systematic reviews of interventions. West Sussex, England: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex.
- 3. Bebarta V, Luyten D, Heard K (2003) Emergency medicine animal research: does use of randomization and blinding affect the results? Acad Emerg Med 10: 684–687.
- 4. Crossley NA, Sena E, Goehler J, Horn J, van der Worp B, et al. (2008) Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke 39: 929–934.
- 5. Minnerup J, Wersching H, Diederich K, Schilling M, Ringelstein EB, et al. (2010) Methodological quality of preclinical stroke studies is not required for publication in high-impact journals. J Cereb Blood Flow Metab 30: 1619–1624.
- 6. Sena ES, Briscoe CL, Howells DW, Donnan GA, Sandercock PA, et al. (2010) Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. J Cereb Blood Flow Metab 30: 1905–1913.
- 7. Vesterinen HM, Sena ES, ffrench-Constant C, Williams A, Chandran S, et al. (2010) Improving the translational hit of experimental treatments in multiple sclerosis. Mult Scler 16: 1044–1055.
- 8. Marshall JC, Deitch E, Moldawer LL, Opal S, Redl H, et al. (2005) Preclinical models of shock and sepsis: what can they tell us? Shock 24 Suppl 1: 1–6.
- 9. National Research Council (2009) Science and decisions: advancing risk assessment. Washington DC: National Academies Press.
- 10. Barnes DE, Bero LA (1996) Industry-funded research and conflict of interest: an analysis of research sponsored by the tobacco industry through the Center for Indoor Air Research. J Health Polit Policy Law 21: 515–542.
- 11. Barnes DE, Bero LA (1997) Scientific quality of original research articles on environmental tobacco smoke. Tob Control 6: 19–26.
- 12. Barnes DE, Bero LA (1998) Why review articles on the health effects of passive smoking reach different conclusions. JAMA 279: 1566–1570.
- 13. Bekelman JE, Li Y, Gross CP (2003) Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289: 454–465.
- 14. Bero L, Oostvogel F, Bacchetti P, Lee K (2007) Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med 4: e184 doi: 10.1371/journal.pmed.0040184.
- 15. Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326: 1167–1170.
- 16. Yank V, Rennie D, Bero LA (2007) Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ 335: 1202–1205.
- 17. Blumenthal D, Campbell EG, Gokhale M, Yucel R, Clarridge B, et al. (2006) Data withholding in genetics and the other life sciences: prevalences and predictors. Acad Med 81: 137–145.
- 18. Campbell EG, Clarridge BR, Gokhale M, Birenbaum L, Hilgartner S, et al. (2002) Data withholding in academic genetics: evidence from a national survey. JAMA 287: 473–480.
- 19. Campbell EG, Powers JB, Blumenthal D, Biles B (2004) Inside the triple helix: technology transfer and commercialization in the life sciences. Health Aff (Millwood) 23: 64–76.
- 20. Davignon J, Laaksonen R (1999) Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 10: 543–559.
- 21. Mundy G, Garrett R, Harris S, Chan J, Chen D, et al. (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946–1949.
- 22. Bandoh T, Mitani H, Niihashi M, Kusumi Y, Kimura M, et al. (2000) Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J Cardiovasc Pharmacol 35: 136–144.
- 23. Sata M, Nishimatsu H, Osuga J, Tanaka K, Ishizaka N, et al. (2004) Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 43: 1214–1220.
- 24. Schroeter MR, Humboldt T, Schafer K, Konstantinides S (2009) Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice. Atherosclerosis 205: 63–73.
- 25. Sukhova GK, Williams JK, Libby P (2002) Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 22: 1452–1458.
- 26. Wang JA, Chen WA, Wang Y, Zhang S, Bi H, et al. (2011) Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms. Atherosclerosis 217: 90–96.
- 27. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L (2012) Industry sponsorship and research outcome. Cochrane Database Syst Rev 12: MR000033.
- 28. Ioannidis JP (2008) Why most discovered true associations are inflated. Epidemiology 19: 640–648.
- 29. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, et al. (2006) 1,026 experimental treatments in acute stroke. Ann Neurol 59: 467–477.
- 30. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, et al. (2007) Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 334: 197.
- 31. Pound P, Ebrahim S, Sandercock P, Bracken MB, Roberts I, et al. (2004) Where is the evidence that animal research benefits humans? BMJ 328: 514–517.
- 32. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, et al. (2010) Can animal models of disease reliably inform human studies? PLoS Med 7: e1000245 doi: 10.1371/journal.pmed.1000245.
- 33. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, et al. (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490: 187–191.
- 34. National Research Council (US) Institute for Laboratory Animal, Research (2011) Guidance for the description of animal research in scientific publications. Washington, DC: National Research Council (US) Institute for Laboratory Animal, Research
- 35. Turner L, Shamseer L, Altman DG, Schulz KF, Moher D (2012) Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev 1: 60.
- 36. Chan AW, Altman DG (2005) Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ 330: 753.
- 37. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG (2004) Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 291: 2457–2465.
- 38. Dickersin K, Chan S, Chalmers TC, Sacks HS, Smith H Jr (1987) Publication bias and clinical trials. Control Clin Trials 8: 343–353.
- 39. Dickersin K, Min YI, Meinert CL (1992) Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 267: 374–378.
- 40. Lee KP, Boyd EA, Holroyd-Leduc JM, Bacchetti P, Bero LA (2006) Predictors of publication: characteristics of submitted manuscripts associated with acceptance at major biomedical journals. Med J Aust 184: 621–626.
- 41. ter Riet G, Korevaar DA, Leenaars M, Sterk PJ, Van Noorden CJ, et al. (2012) Publication bias in laboratory animal research: a survey on magnitude, drivers, consequences and potential solutions. PLoS ONE 7: e43404 doi: 10.1371/journal.pone.0043404.
- 42. Boutron I, Dutton S, Ravaud P, Altman DG (2010) Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303: 2058–2064.
- 43. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, et al. (2004) Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141: 781–788.
- 44. Krauth D, Anglemyer A, Philipps R, Bero L (2014) Non-industry sponsored preclinical studies yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. Dryad Data Submission Openly available via http://dx.doi.org/10.5061/dryad.754d0.
- 45. Krauth D, Woodruff TJ, Bero L (2013) Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. Environ Health Perspect 121: 985–992.
- 46. Duke JL, Zammit TG, Lawson DM (2001) The effects of routine cage-changing on cardiovascular and behavioral parameters in male Sprague-Dawley rats. Contemp Top Lab Anim Sci 40: 17–20.
- 47. Gerdin AK, Igosheva N, Roberson LA, Ismail O, Karp N, et al. (2012) Experimental and husbandry procedures as potential modifiers of the results of phenotyping tests. Physiol Behav 106: 602–611.
- 48. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA (2005) Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab 25: 713–721.
- 49. Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, et al. (2008) Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke 39: 2824–2829.
- 50. Rising K, Bacchetti P, Bero L (2008) Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 5: e217 discussion e217. doi: 10.1371/journal.pmed.0050217.
- 51. Sena E, van der Worp HB, Howells D, Macleod M (2007) How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci 30: 433–439.
- 52. Sniekers YH, Weinans H, Bierma-Zeinstra SM, van Leeuwen JP, van Osch GJ (2008) Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment—a systematic approach. Osteoarthritis Cartilage 16: 533–541.
- 53. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
- 54. Macleod MR, O'Collins T, Howells DW, Donnan GA (2004) Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 35: 1203–1208.